Bondwell Technologies Inc.
High-efficiency endotoxin removal filter using engineered protein-binding materials for pharmaceutical manufacturing and sepsis treatment
- Sector
- Medtech
- Headquarters
- College Station, TX
- Founded
- 2017
- Latest Form D
- $800K, Dec 2017
- Total capital
- $1.3M
- Federal grants
- $484K
- 2 awards · 2019–2020
- Rank in peer group#272 of 542
- Private capital raised
- $800K
- 1 Form D · last Dec 2017
- 106 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 3 pending · first 2025
- Rank in peer group#106 of 542
Capital timeline
Latest events
- Federal grantNSF · Phase I · SBIR Phase I: A high-efficiency filter for endotoxin removal$236K
- Federal grantHealth and Human S · Phase I · A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing$249K
- Private capital raisedForm D · SEC · 1st filing$800K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 542 peers
Line = medianMedtech · Device
- Federal grantsBelow median
- Granted patents#106 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Sarah BondosResearcherExecutive OfficerLinked by 1 patent · $249K in grants as PI
- David HowellResearcherExecutive OfficerLinked by $236K in grants as PI
- Kristin HowellExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 4- GrantedFunctionalized Ubx Protein Materials For Enhanced Purification Of AntibodiesUSPTOUS 12,344,638
- PendingProtein-based Material For BiocatalysisUSPTOApplication 63144755
- PendingFunctionalized Ubx Protein Materials For Enhanced Purification Of AntibodiesUSPTOApplication PCTUS2020026412
Show all 4 patent records
- Functionalized Ubx Protein Materials For Enhanced Purification Of AntibodiesJul 1, 2025 · US 12,344,638Granted
- Protein-based Material For BiocatalysisApplication 63144755Pending
- Functionalized Ubx Protein Materials For Enhanced Purification Of AntibodiesApplication PCTUS2020026412Pending
- Functionalized Ubx Protein Materials For Enhanced Purification Of AntibodiesApplication 62828142Pending
Related companies, and why
- QUICKSILVER BIOSCIENCES, INC.Similar federal contract value in Medtech · null in contracts
- PZA INNOVATION LLCSimilar federal contract value in Medtech · null in contracts
- ERISYON INCSimilar federal contract value in Medtech · null in contracts
- INVICTUS MEDICAL, INC.Similar federal contract value in Medtech · null in contracts
- Pharmateck LLCSimilar federal contract value in Medtech · null in contracts
- MAY & MEADOW, INC.Similar federal contract value in Medtech · null in contracts
Press
Matica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech InnovationPRNewswire
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .